Terms: = Kidney tumors AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Prognosis
54 results:
1. Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.
Xiang J; Liu W; Liu S; Wang T; Tang H; Yang J
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16015-16030. PubMed ID: 37689589
[TBL] [Abstract] [Full Text] [Related]
2. PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S; Nikpanjeh N; Rezaee A; Gholami S; Hashemipour R; Biavarz N; Yousefi F; Tashakori A; Salmani F; Rajabi R; Khorrami R; Nabavi N; Ren J; Salimimoghadam S; Rashidi M; Zandieh MA; Hushmandi K; Wang Y
Eur J Pharmacol; 2023 Sep; 955():175909. PubMed ID: 37490949
[TBL] [Abstract] [Full Text] [Related]
3. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
[TBL] [Abstract] [Full Text] [Related]
4. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
Tamukong PK; Kuhlmann P; You S; Su S; Wang Y; Yoon S; Gong J; Figlin RA; Janes JL; Freedland SJ; Halabi S; Small EJ; Rini BI; Kim HL
Urol Oncol; 2022 Nov; 40(11):495.e1-495.e10. PubMed ID: 35973929
[TBL] [Abstract] [Full Text] [Related]
5. The cancer-testis antigen a-kinase anchor protein 3 facilitates breast cancer progression via activation of the pten/PI3K/AKT/mTOR signaling.
Zhan CH; Ding DS; Zhang W; Wang HL; Mao ZY; Liu GJ
Bioengineered; 2022 Apr; 13(4):8478-8489. PubMed ID: 35322748
[TBL] [Abstract] [Full Text] [Related]
6. OTUD1 stabilizes pten to inhibit the PI3K/AKT and TNF-alpha/NF-kappaB signaling pathways and sensitize ccRCC to TKIs.
Liu W; Yan B; Yu H; Ren J; Peng M; Zhu L; Wang Y; Jin X; Yi L
Int J Biol Sci; 2022; 18(4):1401-1414. PubMed ID: 35280681
[TBL] [Abstract] [Full Text] [Related]
7. miR-96-5p targets pten to mediate sunitinib resistance in clear cell renal cell carcinoma.
Park SE; Kim W; Hong JY; Kang D; Park S; Suh J; You D; Park YY; Suh N; Hwang JJ; Kim CS
Sci Rep; 2022 Mar; 12(1):3537. PubMed ID: 35241735
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive analysis of pten-related ceRNA network revealing the key pathways WDFY3-AS2 - miR-21-5p/miR-221-3p/miR-222-3p - TIMP3 as potential biomarker in tumorigenesis and prognosis of kidney renal clear cell carcinoma.
Zhou X; Liu G; Xu M; Ying X; Li B; Cao F; Cheng S; Xiao B; Cheng M; Liang L; Jia M; Li W; Liu J; Li Z
Mol Carcinog; 2022 May; 61(5):508-523. PubMed ID: 35129856
[TBL] [Abstract] [Full Text] [Related]
9. Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis.
Chen CV; Croom NA; Simko JP; Stohr BA; Chan E
Hum Pathol; 2022 Jan; 119():85-93. PubMed ID: 34800526
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathologic features of TDO2 overexpression in renal cell carcinoma.
Pham QT; Taniyama D; Sekino Y; Akabane S; Babasaki T; Kobayashi G; Sakamoto N; Sentani K; Oue N; Yasui W
BMC Cancer; 2021 Jun; 21(1):737. PubMed ID: 34174844
[TBL] [Abstract] [Full Text] [Related]
11. NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the pten/AKT/mTOR pathway.
He W; Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Zhang T
Aging (Albany NY); 2021 May; 13(10):14015-14038. PubMed ID: 34030133
[TBL] [Abstract] [Full Text] [Related]
12. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.
Liu D; Augello MA; Grbesa I; Prandi D; Liu Y; Shoag JE; Karnes RJ; Trock BJ; Klein EA; Den RB; Demichelis F; Davicioni E; Sboner A; Barbieri CE
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998599
[TBL] [Abstract] [Full Text] [Related]
13. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
[TBL] [Abstract] [Full Text] [Related]
14. Ancestry-specific predisposing germline variants in cancer.
Oak N; Cherniack AD; Mashl RJ; ; Hirsch FR; Ding L; Beroukhim R; Gümüş ZH; Plon SE; Huang KL
Genome Med; 2020 May; 12(1):51. PubMed ID: 32471518
[TBL] [Abstract] [Full Text] [Related]
15. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
[TBL] [Abstract] [Full Text] [Related]
16. Chromophobe renal cell carcinoma: New genetic and metabolic insights.
Zhang L; Henske EP
Urol Oncol; 2020 Aug; 38(8):678-681. PubMed ID: 32444178
[TBL] [Abstract] [Full Text] [Related]
17. Identification of METTL14 in kidney Renal Clear Cell Carcinoma Using Bioinformatics Analysis.
Wang Q; Zhang H; Chen Q; Wan Z; Gao X; Qian W
Dis Markers; 2019; 2019():5648783. PubMed ID: 31976022
[TBL] [Abstract] [Full Text] [Related]
18. Silencing of lncRNA AFAP1-AS1 Inhibits Cell Growth and Metastasis in Clear Cell Renal Cell Carcinoma.
Mu Z; Dong D; Wei N; Sun M; Wang W; Shao Y; Gao J; Yin P; Zhao C
Oncol Res; 2019 Jun; 27(6):653-661. PubMed ID: 30832752
[TBL] [Abstract] [Full Text] [Related]
19. pten in kidney cancer: A review and meta-analysis.
Que WC; Qiu HQ; Cheng Y; Liu MB; Wu CY
Clin Chim Acta; 2018 May; 480():92-98. PubMed ID: 29408173
[TBL] [Abstract] [Full Text] [Related]
20. Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma.
Wei X; Choudhury Y; Lim WK; Anema J; Kahnoski RJ; Lane B; Ludlow J; Takahashi M; Kanayama HO; Belldegrun A; Kim HL; Rogers C; Nicol D; Teh BT; Tan MH
Sci Rep; 2017 Aug; 7(1):7342. PubMed ID: 28779136
[TBL] [Abstract] [Full Text] [Related]
[Next]
